GLP-1 receptor agonists vie for diabetes market share
This article was originally published in Scrip
Executive Summary
After enjoying almost five years of exclusivity, Lilly/Amylin's first-in-class antidiabetic GLP-1 receptor analogue Byetta (exenatide) has started to feel competition nipping at its heels. Asher Mullard investigates the future for this growing drug class and the next-generation therapeutics that are jockeying for position.